Skip to contentpdufa.bio

rilparencel PROACT

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

rilparencel PROACT is a Prokidney Corp. program in advanced CKD with type 2 diabetes. Its next catalyst is a Readout in Q2 2027.

PROK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Advanced CKD with type 2 diabetes. Sponsor: Prokidney Corp. (PROK). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027PROKReadout · Q4 2029PROK

Questions

When is rilparencel PROACT's next FDA decision or readout?

The next tracked catalyst for rilparencel PROACT is a Readout in Q2 2027.

What happened at rilparencel PROACT's most recent FDA decision?

No FDA decision for rilparencel PROACT is in our archive yet.

What is rilparencel PROACT used for?

In our records rilparencel PROACT is under review or in development for Advanced CKD with type 2 diabetes.

Who makes rilparencel PROACT?

Prokidney Corp. (PROK).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.